Clinical Trial Update: Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and immune responses of a heterologous prime-boost DNA vaccine (pNGVL4a-Sig/E7(Detox)/HSP70) with TA-HPV in individuals…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-related Cancer
• Human Papillomavirus Infection

Drugs mentioned

• TA-HPV
• pNGVL4a-Sig/E7(Detox)/HSP70

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: HPV 16 Infection, HPV-Related Carcinoma | Phase 1 | Status: ENROLLING_BY_INVITATION